Latest Articles
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - NTB Kommunikasjon
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 NTB Kommunikasjon
Published: June 14, 2026, 10:05 p.m.
Endometrial Cancer, Sri Lanka’s Commonest Gynaecological Cancer - dailynews.lk
Endometrial Cancer, Sri Lanka’s Commonest Gynaecological Cancer dailynews.lk
Published: June 14, 2026, 7:42 p.m.
Incyte’s POD1UM-204 Endometrial Cancer Study Wraps Up, Setting the Stage for Key Retifanlimab Data - TipRanks
Incyte’s POD1UM-204 Endometrial Cancer Study Wraps Up, Setting the Stage for Key Retifanlimab Data TipRanks
Published: June 11, 2026, 4:35 p.m.
Bulletin: GLP-1RAs Help Reduce Obesity Related Cancers - Medical News Bulletin
Bulletin: GLP-1RAs Help Reduce Obesity Related Cancers Medical News Bulletin
Published: June 11, 2026, 2:44 p.m.
GLP-1 RAs Help Reduce Obesity Related Cancers - Medical News Bulletin
GLP-1 RAs Help Reduce Obesity Related Cancers Medical News Bulletin
Published: June 11, 2026, 2:37 p.m.
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies - The Malaysian Reserve
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies The Malaysian Reserve
Published: June 11, 2026, 6:33 a.m.
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies - StreetInsider
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies StreetInsider
Published: June 11, 2026, 5:42 a.m.
Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected? - The Guardian
Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected? The Guardian
Published: June 10, 2026, 9:17 p.m.
Four-Year RUBY Data Support Curative Intent With Dostarlimab in dMMR/MSI-H Endometrial Cancer - The ASCO Post
Four-Year RUBY Data Support Curative Intent With Dostarlimab in dMMR/MSI-H Endometrial Cancer The ASCO Post
Published: June 10, 2026, 4:41 p.m.
“I Dismissed It as Menopause”—One Woman’s Endometrial Cancer Story - Chatelaine
“I Dismissed It as Menopause”—One Woman’s Endometrial Cancer Story Chatelaine
Published: June 9, 2026, 7:04 p.m.
Link copied to clipboard!